Genmab A/s Share Price: GMAB (Genmab A/s) Stock Price Today & Updates | INDmoney

Question 1

What is Genmab A/s share price today?

Accepted Answer

Genmab A/s (GMAB) share price today is {{live_price}}.

Question 2

Can Indians buy Genmab A/s shares?

Accepted Answer

Yes, Indians can invest in the Genmab A/s (GMAB) from India.

With INDmoney, you can buy Genmab A/s at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Genmab A/s at zero transaction cost.

Question 3

How can I buy Genmab A/s shares from India?

Accepted Answer

It is very easy to buy Genmab A/s from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Question 4

Can Fractional shares of Genmab A/s be purchased?

Accepted Answer

Yes, you can buy fractional shares of Genmab A/s with INDmoney app.

Question 5

What are the documents required to start investing in Genmab A/s stocks?

Accepted Answer

To start investing in Genmab A/s, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

Question 6

What are today’s High and Low prices of Genmab A/s

Accepted Answer

Today’s highest price of Genmab A/s (GMAB) is {{1_rba_end}}.

Today’s lowest price of Genmab A/s (GMAB) is {{1_rba_st}}.

Question 7

What is today's market capitalisation of Genmab A/s

Accepted Answer

Today's market capitalisation of Genmab A/s GMAB is 17.7B

Question 8

What is the 52 Week High and Low Range of Genmab A/s

Accepted Answer

52 Week High
{{rba_end}}
52 Week Low
{{rba_st}}

Question 9

How much percentage Genmab A/s is down from its 52 Week High?

Accepted Answer

Genmab A/s (GMAB) share price is {{live_price}}. It is down by {{w52lu}}% from its 52 Week High price of {{rba_end}}.

Question 10

How much percentage Genmab A/s is up from its 52 Week low?

Accepted Answer

Genmab A/s (GMAB) share price is {{live_price}}. It is up by {{w52hd}}% from its 52 Week Low price of {{rba_st}}.

Question 11

What are the historical returns of Genmab A/s?

Accepted Answer

1 Month Returns
{{1mr}}%
3 Months Returns
{{3mr}}%
1 Year Returns
{{1yr}}%
5 Years Returns
{{5yr}}%

Question 12

Who is the Chief Executive Officer (CEO) of Genmab A/s

Accepted Answer

Dr. Jan G.J. van de Winkel Ph.D. is the current Chief Executive Officer (CEO) of Genmab A/s.

Period	Genmab A/s	Sector (Health Care)	Index (Russel 2000)
3 Months	-0.07%	6.5%	0.0%
6 Months	0.75%	7.1%	0.0%
1 Year	-28.13%	9.8%	0.0%
3 Years	-36.18%	14.2%	-20.2%

Market Capitalization	17.7B
Book Value	$498.87
Earnings Per Share (EPS)	1.21
PE Ratio	23.04
PEG Ratio	1.27
Wall Street Target Price	41.53

Profit Margin	30.74%
Operating Margin TTM	19.33%

Return On Assets TTM	10.63%
Return On Equity TTM	18.32%

Revenue TTM	17.8B
Revenue Per Share TTM	27.24
Quarterly Revenue Growth YOY	45.2%
Gross Profit TTM	14.6B
EBITDA	6.0B
Diluted Eps TTM	1.21
Quarterly Earnings Growth YOY	4.88

Genmab A/s (GMAB)

Performance

Returns

Highlights

Analyst Recommendation

Analyst Forecast

Company Financials

Technicals Summary

Peers

Decreasing Revenue

Increasing Net Profit

Vs NVO

Vs NVO

Institutional Holdings

Company Information

Discover More

FAQs

EPS Estimate Current Year	1.1
EPS Estimate Next Year	1.3
EPS Estimate Current Quarter	0.14
EPS Estimate Next Quarter	0.3

	FY18	Y/Y Change
Revenue	463.5M	↑ 27.89%
Net Income	225.5M	↑ 33.4%
Net Profit Margin	48.66%	↑ 2.01%

	FY19	Y/Y Change
Revenue	804.5M	↑ 77.38%
Net Income	324.8M	↑ 47.13%
Net Profit Margin	40.37%	↓ 8.29%

	FY20	Y/Y Change
Revenue	1.7B	↑ 88.43%
Net Income	786.5M	↑ 119.67%
Net Profit Margin	47.06%	↑ 6.69%

	FY21	Y/Y Change
Revenue	1.3B	↓ 16.11%
Net Income	450.2M	↓ 37.85%
Net Profit Margin	34.86%	↓ 12.2%

	FY22	Y/Y Change
Revenue	2.1B	↑ 72.07%
Net Income	784.8M	↑ 84.38%
Net Profit Margin	37.36%	↑ 2.5%

	FY23	Y/Y Change
Revenue	2.4B	↑ 12.87%
Net Income	644.5M	↓ 20.18%
Net Profit Margin	26.42%	↓ 10.94%

	Q4 FY22	Q/Q Change
Revenue	752.4M	↑ 27.89%
Net Income	84.1M	↓ 77.38%
Net Profit Margin	11.17%	↓ 52.01%

	Q1 FY23	Q/Q Change
Revenue	417.8M	↓ 45.4%
Net Income	30.7M	↓ 64.04%
Net Profit Margin	7.36%	↓ 3.81%

	Q2 FY23	Q/Q Change
Revenue	615.3M	↑ 47.09%
Net Income	198.9M	↑ 546.19%
Net Profit Margin	32.32%	↑ 24.96%

	FY19	Y/Y Change
Total Assets	2.3B	↑ 78.99%
Total Liabilities	164.3M	↑ 145.39%

	FY20	Y/Y Change
Total Assets	3.5B	↑ 39.61%
Total Liabilities	334.2M	↑ 84.49%

	FY21	Y/Y Change
Total Assets	3.7B	↑ 16.48%
Total Liabilities	370.1M	↑ 20.23%

	FY22	Y/Y Change
Total Assets	4.4B	↑ 22.95%
Total Liabilities	408.4M	↑ 16.7%

	Q3 FY23	Q/Q Change
Revenue	4.7B	↑ 13.01%
Net Income	2.1B	↑ 56.89%
Net Profit Margin	44.88%	↑ 12.56%

	Q4 FY23	Q/Q Change
Revenue	692.7M	↓ 1.39%
Net Income	94.8M	↓ 69.94%
Net Profit Margin	13.68%	↓ 31.2%

	Q1 FY24	Q/Q Change
Revenue	599.6M	↓ 11.44%
Net Income	191.8M	↑ 107.03%
Net Profit Margin	31.98%	↑ 18.3%

	FY18	Y/Y Change
Operating Cash Flow	155.5M	↓ 36.14%
Investing Cash Flow	-272.4M	↑ 166.34%
Financing Cash Flow	-10.9M	↓ 132.99%

	FY19	Y/Y Change
Operating Cash Flow	198.8M	↑ 30.67%
Investing Cash Flow	-297.3M	↑ 11.53%
Financing Cash Flow	548.8M	↓ 5262.13%

	FY20	Y/Y Change
Operating Cash Flow	1.1B	↑ 385.14%
Investing Cash Flow	-388.6M	↑ 18.56%
Financing Cash Flow	11.7M	↓ 98.06%

	FY21	Y/Y Change
Operating Cash Flow	339.2M	↓ 65.37%
Investing Cash Flow	-146.3M	↓ 59.12%
Financing Cash Flow	-63.9M	↓ 691.55%

	FY22	Y/Y Change
Operating Cash Flow	563.1M	↑ 75.58%
Investing Cash Flow	-397.4M	↑ 187.3%
Financing Cash Flow	-113.6M	↑ 87.86%

	Q4 FY22	Q/Q Change
Operating Cash Flow	57.3M	↓ 79.78%
Investing Cash Flow	-19.6M	↓ 90.16%
Financing Cash Flow	18.9M	↓ 120.4%

	Q1 FY23	Q/Q Change
Operating Cash Flow	473.6M	↑ 712.81%
Investing Cash Flow	-268.7M	↑ 1249.26%
Financing Cash Flow	-89.5M	↓ 566.41%

	Q2 FY23	Q/Q Change
Operating Cash Flow	63.9M	↓ 86.52%
Investing Cash Flow	-269.0M	↑ 0.0%
Financing Cash Flow	1.0M	↓ 101.15%

	Q3 FY23	Q/Q Change
Operating Cash Flow	2.0B	↑ 367.2%
Investing Cash Flow	1.0B	↓ 154.93%
Financing Cash Flow	20.0M	↑ 185.71%

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Genmab A/s	9.58%	0.75%	-28.13%	-36.18%	51.32%
Moderna, Inc.	-1.67%	18.26%	-0.21%	-64.15%	752.69%
Regeneron Pharmaceuticals, Inc.	-0.46%	13.21%	45.59%	84.19%	244.2%
Novo Nordisk A/s	-11.0%	18.31%	61.56%	186.46%	423.59%
Vertex Pharmaceuticals Incorporated	3.85%	14.43%	39.88%	147.45%	195.07%

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Genmab A/s	Buy	$17.7B	51.32%	23.04	30.74%
Moderna, Inc.	Buy	$45.3B	752.69%	24.73	-115.82%
Regeneron Pharmaceuticals, Inc.	Buy	$116.9B	244.2%	31.35	29.45%
Novo Nordisk A/s	Buy	$572.0B	423.59%	44.28	36.55%
Vertex Pharmaceuticals Incorporated	Buy	$126.7B	195.07%	31.85	39.46%

Organization	Genmab A/s
Employees	2286
CEO	Dr. Jan G.J. van de Winkel Ph.D.
Industry	Health Technology